Essentials for Clinicians: Lymphomas - Editors and Contributors

Editors

Michele Ghielmini
Oncology Institute of Southern Switzerland, Ospedale San Giovanni, Bellinzona, Switzerland

Silvia Montoto
Department of Haemato-Oncology, St Bartholomew’s Hospital, London, UK

Contributors

Chapter 1: The Immune System

Davies A. Cancer Sciences Unit, Faculty of Medicine, University of Southampton, Southampton, UK

Chapter 2: Diagnosing Lymphomas

Soldini D. Istituto Cantonale di Patologia, Locarno, Switzerland

Mazzucchelli L. Istituto Cantonale di Patologia, Locarno, Switzerland

Chapter 3: The WHO Lymphoma Classification

Carvajal-Cuenca A. Department of Pathology, Hospital Mexico, University of Costa Rica, San José, Costa Rica

Campo E. Department of Pathology, Hospital Clinic, University of Barcelona, Barcelona, Spain

Chapter 4: Staging and Response Assessment in Lymphoma Patients

Borra A. Haematology Department and BMT Unit, Azienda Ospedaliera S. Croce e Carle, Cuneo, Italy

Gallamini A. Research, Innovation and Statistics Department, A Lacassagne Cancer Center, Nice, France

Chapter 5: Common Treatments for Lymphoma

Rodriguez-Abreu D. Medical Oncology Department, Hospital Universitario Insular de Gran Canaria, Las Palmas de Gran Canaria, Spain

Provencio M. Medical Oncology Department, Hospital Universitario Puerta de Hierro Majadahonda, Madrid, Spain

Chapter 6: Diffuse Large B-Cell Lymphoma

Chiappella A. Hematology 2, Città della Salute e della Scienza, San Giovanni Battista Hospital and University, Torino, Italy

Vitolo U. Hematology, Città della Salute e della Scienza, Hospital and University, Torino, Italy

Chapter 7: Follicular Lymphoma

Moccia A.A. Oncology Institute of Southern Switzerland, Ospedale San Giovanni, Bellinzona, Switzerland

Ghielmini M. Oncology Institute of Southern Switzerland, Ospedale San Giovanni, Bellinzona, Switzerland

Chapter 8: Chronic Lymphocytic Leukaemia / Small Lymphocytic Lymphoma

Norin S. Division of Hematology, Department of Medicine at Huddinge, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden

Kimby E. Division of Hematology, Department of Medicine at Huddinge, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden

Chapter 9: Mantle Cell Lymphoma

Weiglein T. Department of Medicine III, Klinikum der Universität München, München, Germany

Dreyling M. Department of Medicine III, Klinikum der Universität München, München, Germany

Chapter 10: Extranodal marginal Zone Lymphoma of MALT Type

Bertoni F. Lymphoma and Genomics Research Program, IOR Institute of Oncology Research, Oncology Institute of Southern Switzerland, Bellinzona, Switzerland

Zucca E. Division of Research, Oncology Institute of Southern Switzerland, Bellinzona, Switzerland

Chapter 11: Peripheral T-Cell Lymphomas

Pedersen M.B. Department of Hematology, Aarhus University Hospital, Aarhus, Denmark

d’Amore F. Department of Hematology, Aarhus University Hospital, Aarhus, Denmark

Chapter 12: Hodgkin Lymphoma

Eichenauer D.A. First Department of Internal Medicine, University Hospital Cologne; German Hodgkin Study Group (GHSG), University Hospital Cologne, Cologne, Germany

Engert A. First Department of Internal Medicine, University Hospital Cologne; German Hodgkin Study Group (GHSG), University Hospital Cologne, Cologne, Germany

Chapter 13: Aetiology and Epidemiology

Costas L. Unit of Infections and Cancer, Cancer Epidemiology Research Programme, IDIBELL, Catalan Institute of Oncology, Barcelona; CIBER Epidemiologia y Salud Publica, Madrid, Spain

de Sanjose S. Unit of Infections and Cancer, Cancer Epidemiology Research Programme, IDIBELL, Catalan Institute of Oncology, Barcelona; CIBER Epidemiologia y Salud Pública, Madrid, Spain

Chapter 14: History of Lymphoma Classification

Ponzoni M. Vita-Salute San Raffaele University, Haematopathology Diagnostic Area - Pathology Unit, Lymphoma, Leukemia and Myeloma Units, Division of Experimental Oncology, IRCCS San Raffaele Scientific Institute, Milano, Italy

Ferreri A.J.M. Unit of Lymphoid Malignancies, Division of Onco-Hematological Medicine, Department of Onco-Hematology, IRCCS San Raffaele Scientific Institute, Milan, Italy

Chapter 15: Molecular Biology of Lymphomas

Bertoni F. Lymphoma and Genomics Research Program, IOR Institute of Oncology Research, Oncology Institute of Southern Switzerland, Bellinzona, Switzerland

Chapter 16: New Drugs and Novel Treatment Strategies

Hess G. Department of Internal Medicine, Hematology, Oncology and Pneumology, University Medical School of the Johannes Gutenberg-Universität, Mainz, Germany

Chapter 17: Cutaneous Lymphoma

Willemze R. Department of Dermatology, Leiden University Medical Center, Leiden, The Netherlands

Chapter 18: Peripheral T-Cell Lymphomas (Extranodal)

Ballova V. National Cancer Institute (Narodny Onkologicky Ustav), Bratislava, Slovakia

Chapter 19: Non-MALT Marginal Zone Lymphomas

Montalban C. Department of Hematology, MD Anderson Cancer Center, Madrid, Spain

Chapter 20: Lymphoplasmacytic Lymphoma / Waldenström’s Macroglobulinemia

Kastritis E. Department of Clinical Therapeutics, National and Kapodistrian University of Athens School of Medicine, Athens, Greece

Dimopoulos M.A. Department of Clinical Therapeutics, National and Kapodistrian, University of Athens School of Medicine, Athens, Greece

Chapter 21: Burkitt Lymphoma and Lymphoblastic Lymphoma

Fridrik M.A. Department of Internal Medicine 3, Center for Hematology and Medical Oncology, Medical Faculty Johannes Kepler University, Linz, Austria

Chapter 22: Extranodal Lymphomas

Ferreri A.J.M. Unit of Lymphoid Malignancies, Division of Onco-Hematological Medicine, Department of Onco-Hematology, IRCCS San Raffaele Scientific Institute, Milan, Italy

Ponzoni M. Vita-Salute San Raffaele University, Haematopathology Diagnostic Area - Pathology Unit, Lymphoma, Leukemia and Myeloma Units, Division of Experimental Oncology, IRCCS San Raffaele Scientific Institute, Milano, Italy

Chapter 23: Lymphomas in the Immunocompromised Patient

Montoto S. Department of Haemato-oncology, St Bartholomew’s Hospital, London, UK

Declarations of Interest

V Ballova: No conflicts of interest.

F Bertoni: Received funds for research projects or advisory board participation from: Bayer, CTI Life Sciences, Celgene, EMD Serono Research, Italfarmaco, Oncoethix, Piqur, Sigma Tau.

A Borra: No conflicts of interest.

E Campo: No conflicts of interest.

A Carvajal-Cuenca: No conflicts of interest.

A Chiappella: No conflicts of interest.

L Costas: No conflicts of interest.

F d’Amore: Research funding: Sanofi, Amgen; Advisory board/speaker honoraria: Takeda/Millennium, CTI, Roche, Bayer, Kyowa-Kirin.

A Davies: No conflicts of interest.

MA Dimopoulos: Honoraria from Celgene, Janssen, Onyx.

M Dreyling: No conflicts of interest.

DA Eichenauer: No conflicts of interest.

A Engert: Research funding/consultancy: Millennium/Takeda, Affimed.

AJM Ferreri: No conflicts of interest.

MA Fridrik: Consultant or advisory role: Roche Austria; Honoraria: Roche Austria; Other remuneration: Roche Austria.

A Gallamini: No conflicts of interest.

M Ghielmini: Honoraria: Roche, Millennium, Mundipharma, Celgene, Janssen, Gilead.

G Hess: Research funding: Roche, Mundipharma, Pfizer, CTI, Celgene; Advisory board /Speaker honoraria: Roche, Janssen, Celgene, Pfizer, CTI, Novartis.

E Kastritis: No conflicts of interest.

E Kimby: Conducting research in part sponsored by Roche and Pfizer; Advisory boards: Janssen, Gilead, Pharmacyclics; Educational talks in meetings sponsored with unrestricted grants from Roche and Celgene.

L Mazzucchelli: No conflicts of interest.

AA Moccia: No conflicts of interest.

C Montalban: No conflicts of interest.

S Montoto: Honoraria: Roche.

S Norin: Grant and lecture honoraria: Roche; Lecture honoraria: Mundipharma; National principal nvestigator in a company-sponsored study: Janssen-Cilag: Local principal investigator in company-sponsored studies: GlaxoSmithKline.

MB Pedersen: No conflicts of interest.

M Ponzoni: No conflicts of interest.

M Provencio: No conflicts of interest.

D Rodriguez-Abreu: No conflicts of interest.

S de Sanjose: No conflicts of interest.

D Soldini: No conflicts of interest.

U Vitolo: Advisory board/speakers’ bureau: Roche, Celgene, Janssen, Mundipharma.

T Weiglein: No conflicts of interest.

R Willemze: Advisory board/speakers’ bureau: Takeda, Actelion, Excerpta Medica.

E Zucca: Funds for research projects or advisory board participation from: Celgene, GlaxoSmithKline, Mundipharma, Oncoethix, Novartis, Roche.

« Previous Page Next Page »

Last update: 01 June 2015